{"filings":[{"id":500079,"accession_number":"0001193125-26-229013","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2026-05-18T20:30:20+00:00","items":["5.07"],"status":"ready","headline":"biote Corp. 2026 annual meeting elects directors, ratifies Deloitte as auditor","event_type":"other_material","confidence":"high","bullets":["Andrew R. Heyer elected Class I director with 22,759,692 for, 3,960,800 withheld; 2,861,704 broker non-votes.","Dana Jacoby elected Class I director with 23,020,635 for, 3,699,857 withheld; 2,861,704 broker non-votes.","Stockholders ratified Deloitte & Touche as auditor for FY2026: 29,507,419 for, 67,387 against, 7,390 abstain.","Annual meeting held May 12, 2026; described in proxy statement filed April 2, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95763,"accession_number":"0001193125-26-208965","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q1 revenue $44.9M (-8.3% YoY); net income $2.7M vs $15.8M, hit by hormone pellet recall","event_type":"earnings","confidence":"high","bullets":["Revenue $44.9M, down 8.3% YoY; net income $2.7M ($0.06 EPS) vs $15.8M ($0.37) in Q1 2025.","Procedure revenue fell 13.2% to $31.3M due to voluntary recall of Asteria Health hormone pellets; supplements up 19.1% to $11.0M.","Gross margin 68.9% vs 74.3% from higher replacement costs and reduced manufacturing efficiency at Asteria.","Adjusted EBITDA $8.7M (19.4% margin); sales team expansion nearing target of 120 representatives.","Management expects return to procedure growth in second half of 2026 after recall impact."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":44935000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95762,"accession_number":"0001193125-26-142147","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"biote Corp. posts April 2026 investor presentation on its website","event_type":"other_material","confidence":"low","bullets":["Presentation dated April 2026 available at ir.biote.com/news-events/presentations.","No financial results, guidance changes, or material events disclosed in the 8-K.","Presentation titled 'Transforming Healthy Aging' contains strategic updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109058,"accession_number":"0001193125-26-102129","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q4 revenue $46.4M; net income $2.6M; anticipates procedure growth H2 2026","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $46.4M, gross margin 68.0%; net income $2.6M ($0.06 diluted EPS), down from $3.5M ($0.10) in Q4 2024.","Full year 2025 revenue $192.2M; net income $31.6M ($0.74 diluted EPS), versus $0.05M ($0.09) in 2024.","Adjusted EBITDA Q4 $11.7M (25.2% margin); full year adjusted EBITDA $53.5M (27.8% margin).","CEO Bret Christensen anticipates return to procedure revenue growth in second half of 2026.","Company rebuilding commercial sales coverage; commercial transition impacted 2025 results as expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109057,"accession_number":"0001193125-26-022818","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Biote subsidiary recalls hormone pellets due to metal particulate; expects $1.3M Q4 charge","event_type":"regulatory","confidence":"high","bullets":["Asteria Health voluntarily recalled specific lots of hormone pellets shipped May 20, 2025–Jan 19, 2026 due to potential metal particulate.","Expects ~$1.3M one-time charge in Q4 2025 cost of products for write-off of impacted inventory.","Additional recall costs in 2026 estimated at ~$1.0M; recall conducted with FDA knowledge.","Company states recall does not materially impact ability to supply practitioners or service patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125525,"accession_number":"0001193125-25-266910","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q3 2025: Revenue $48.0M, net income $9.2M ($0.22 EPS), down YoY","event_type":"earnings","confidence":"high","bullets":["Revenue $48.0M, gross profit margin 71.8%.","Net income $9.2M ($0.22 diluted EPS) vs $12.7M ($0.33) in Q3 2024.","Adjusted EBITDA $12.9M (26.9% margin).","Repurchased ~1 million shares of Class A common stock during Q3.","Reiterated 2025 financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":145811000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142261,"accession_number":"0000950170-25-104014","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q2 rev $48.9M, net income $3.9M vs year-ago loss; Adj. EBITDA up 19%","event_type":"earnings","confidence":"high","bullets":["Revenue $48.9M, gross margin 71.6%; net income $3.9M ($0.10 diluted EPS) vs net loss $10.4M ($0.21 loss) in Q2 2024.","Adjusted EBITDA $15.2M (margin 31.1%), up 19.1% YoY; benefit from Q3 shift of annual marketing event and 503B vertical integration.","CEO announced organizational restructuring in early May to accelerate new provider and clinic growth; new leadership and upgraded sales compensation.","Q2 revenue decreased slightly YoY, but profitability and margins expanded significantly."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":97855000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160272,"accession_number":"0001193125-25-137873","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"biote Corp appoints Rich Barrera to Board, filling Heyer vacancy","event_type":"leadership","confidence":"high","bullets":["Richard R. Barrera appointed as Class II director effective June 5, 2025; term expires at 2027 annual meeting.","Barrera is Founder & CEO of Roystone Capital, a top institutional shareholder; considered independent.","Appointed to Nominating and Corporate Governance Committee; eligible for non-employee director compensation.","Initial equity award of $337,500 in stock options vesting over 3 years; annual cash retainer of $50,000.","Barrera replaces Steven J. Heyer, who resigned; has 20+ years investment experience and an MBA from Harvard."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160271,"accession_number":"0001193125-25-135341","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Steven J. Heyer resigns from biote Corp board effective June 2, 2025","event_type":"leadership","confidence":"high","bullets":["Steven J. Heyer resigned from the board of directors effective June 2, 2025.","Resignation was not due to any disagreement with the company on operations, policies, or practices.","Board has not yet selected a replacement for the vacancy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}